Mylan Calcitriol

Calcitriol by Mylan is a pharmaceutical product primarily used to treat calcium deficiency and bone diseases. The product belongs to a portfolio that has undergone significant corporate changes in recent years.

Originally, Mylan was a prominent American generic drug manufacturer. In 2020, Mylan merged with Upjohn (a division of Pfizer) to form a new global healthcare company called Viatris. This merger consolidated several well-known brands and generic lines under one corporate umbrella.

Manufacturing takes place across a specialized global network. Depending on the specific market and formulation, production may occur in facilities located in Europe, India, or the United States. Following the 2020 merger, Viatris serves as the ultimate owner, managing the distribution and production of these essential medications worldwide.